SCHEMBL5844265

SCHEMBL5844265

CCC(CC)Nc1nc(C)nc(Oc2c(C)cc(C)nc2C)c1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 10/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5844675 0.88 CRHR1 (0.50) CRHR1
SCHEMBL8345248 0.82 CRHR1 (0.34) CRHR1
SCHEMBL6432632 0.81 ALDH1A1 (0.38) CRHR1
SCHEMBL5843954 0.79 CRHR1 (0.41) CRHR1
SCHEMBL11677180 0.76 MEN1 (0.35) CRHR1
SCHEMBL5843144 0.75 CRHR1 (0.69) CRHR1
SCHEMBL5844044 0.73 CRHR1 (0.57) CRHR1
SCHEMBL6428930 0.72 CRHR1 (0.34) CRHR1
SCHEMBL5843388 0.71 CRHR1 (0.48) CRHR1
SCHEMBL5843803 0.70 CRHR1 (0.38) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067664-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2006-06-27 US claimed
US-6403599-B1 STROKE, HYPERTENSION, TACHYCARDIA, AND CONGESTIVE HEART FAILURE, OSTEOPOROSIS, PREMATURE BIRTH, PSYCHOSOCIAL DWARFISM, STRESS-INDUCED FEVER, ULCER, DIARRHEA, POST-OPERATIVE ILEUS, AND COLONIC HYPERSENSITIVITY, CARDIOVASCULAR DISORDERS PFIZER INC 2002-06-11 US claimed
US-6387894-B1 MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS PFIZER INC. 2002-05-14 US claimed
US-6384039-B1 ADMINISTERING CORTICOTROPIN RELEASING FACTOR ANTAGONIST PFIZER INC. 2002-05-07 US claimed
US-20010000340-A1 New uses for corticotropin releasing factor antagonists CHEN YUHPYNG L (US) 2001-04-19 US claimed
EP-1059100-A2 Combinations of CRF antagonists and renin-angiotensin system inhibitors Pfizer Products Inc. (US) 2000-12-13 EP claimed
EP-1040831-A2 Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death Pfizer Products Inc. (US) 2000-10-04 EP claimed
EP-0764166-B1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER (US) 2000-09-13 EP claimed
EP-0773023-A1 New uses for corticotropin releasing factor (CRF) antagonists PFIZER INC. (US) 1997-05-14 EP claimed
EP-0764166-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1997-03-26 EP claimed
WO-1995033750-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1995-12-14 WO claimed
US-7125880-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2006-10-24 US disclosed
US-7067664-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2006-06-27 US disclosed
US-6956047-B1 Corticotropin releasing factor antagonists PFIZER INC. (US) 2005-10-18 US disclosed
US-20050032846-A1 Corticotropin releasing factor antagonists PFIZER INC. 2005-02-10 US disclosed
EP-1059100-A2 Combinations of CRF antagonists and renin-angiotensin system inhibitors Pfizer Products Inc. (US) 2000-12-13 EP disclosed
EP-0764166-B1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER (US) 2000-09-13 EP disclosed
EP-0773023-A1 New uses for corticotropin releasing factor (CRF) antagonists PFIZER INC. (US) 1997-05-14 EP disclosed
EP-0764166-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1997-03-26 EP disclosed
WO-1995033750-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER INC. (US) 1995-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000340-A1 New uses for corticotropin releasing factor antagonists CRH, CRHR1, CRHR2 CRHR1 2/4885
US-20050032846-A1 Corticotropin releasing factor antagonists CRH, CRHR2, CRHR1 CRHR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.